A selective cyclooxygenase-2 inhibitor suppresses the growth of endometriosis xenografts via antiangiogenic activity in severe combined immunodeficiency mice

Yuka Ozawa, Ozawa Y, Takashi Murakami, Murakami T, Mitsutoshi Tamura, Tamura M, Yukihiro Terada, Terada Y, Yaegashi N, Nobuo Yaegashi, Kunihiro Okamura, Okamura K
Fertility and sterility · 2006 · vol. 86(4) , pp. 1146–1151 · doi:10.1016/j.fertnstert.2006.01.057 · PMID:16962108 · W2163891312
article OA: bronze CC0 ⤵ 61 in-corpus citations
🔓 Open OA copy View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This study investigated the antiangiogenic effects of a selective cyclooxygenase-2 inhibitor on endometriosis xenografts, observing suppression of tumor growth in SCID mice.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

ObjectiveTo investigate the effects of a selective cyclooxygenase (COX)-2 inhibitor on endometriosis xenografts in immunodeficient mice.DesignProspective placebo-controlled study.SettingAn academic facility at a Japanese university graduate school of medicine.Patient(s)Eight human ovarian endometriomas from seven patients.Animal(s)Twenty-three female severe combined immunodeficiency (SCID) mice.Intervention(s)Human ovarian endometriomas were implanted into the peritonea of SCID mice. Vehicle alone or NS398 (a selective COX-2 inhibitor, 10 mg/kg of weight per day) were administered orally daily for 56 days after implantation. Mice were killed on the 56th day.Main outcome measure(s)Change in explants size and immunohistochemical analyses to evaluating the proliferation index, apoptosis index, microvessel density, and labeling index assessing vascular endothelial growth factor and COX-2 expression by the endometriotic lesion.Result(s)NS398 significantly decreased implant size in comparison to vehicle alone (NS398 [medians, with range in brackets]: 22.0% [19.0%-36.7%] vs. vehicle: 41.2% [31.0%-55.3%], P<.01). Microvessel density (85.3 per mm2 [53.9-157.0 per mm2] vs. 121.8 per mm2 [97.2-259.6 per mm2], P=.02) and the vascular endothelial growth factor (0.4 [0-1.1] vs. 0.6 [0.5-2.1], P=.03) and COX-2 (0.4 [0.4-0.5] vs. 0.6 [0.4-0.8], P=.03) labeling indices in stromal cells were significantly lower in the NS398 group than in the vehicle group. There were no differences in the proliferation or apoptosis indices between the two groups.Conclusion(s)Selective COX-2 inhibitors decreased the size of implants and effectively treated endometriosis.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Angiogenesis Inhibitors Cyclooxygenase 2 Inhibitors Endometriosis Endometriosis Mice, SCID Neovascularization, Pathologic Nitrobenzenes Sulfonamides Adult Angiogenesis Inhibitors Animals Apoptosis Blood Vessels Blood Vessels Cell Proliferation Cell Proliferation Cyclooxygenase 2 Inhibitors Endometriosis Endometriosis Female

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (43)

Cited by (50)

Source provenance

europepmc
last seen: 2026-07-28T06:14:09.330459+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:15:12.369988+00:00
License: CC0 · commercial use OK